Trial Profile
Phase 1, six-month, open-label, multisite, dose- ranging study evaluating the pharmacokinetics (PK) of risperidone and its active metabolite following Risperidone Implant.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2018
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 01 Jan 2018 Results assessing Pharmacokinetics and Safety of Risperidone Subcutaneous Implants in two phase 1 studies, published in the Clinical Pharmacology in Drug Development
- 26 Jul 2017 New trial record